Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (7 quarters reported)
$104M in Q4 2021 → $110M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Omada Health Inc | 97.3% | Trimmed 6.7% | 4,858,034 | $107M |
| Artiva Biotherapeutics Inc | 2.7% | Unchanged | 299,311 | $2.9M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 6 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Omada Health Inc | Trimmed | −350,000 | −$7.68M | 97.3% |
quarter ended March 31, 2026 · filed May 15, 2026
No position changes this quarter.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Omada Health Inc | New | +5,208,034 | +$82.2M | 98.5% |
| Singular Genomics Systems Inc | Exited | −1,415,846 | −$3.54M | — |
| Artiva Biotherapeutics Inc | New | +299,311 | +$1.28M | 1.5% |
| Akili Inc | Exited | −245,912 | −$556K | — |
| Neuropace Inc | Exited | −42,972 | −$161K | — |
quarter ended September 30, 2022 · filed November 07, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Neuropace Inc | Trimmed | −205,155 | −$769K | 3.8% |
| Akili Inc | New | +245,912 | +$556K | 13.1% |
| Accolade Inc | Exited | −58,050 | −$430K | — |
quarter ended June 30, 2022 · filed August 15, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| 2H 23andme Holding Co | Exited | −2,667,736 | −$10.2M | — |
| Singular Genomics Systems Inc | Trimmed | −804,105 | −$3.07M | 76.5% |
| Neuropace Inc | Trimmed | −132,578 | −$656K | 17.4% |
| Accolade Inc | New | +58,050 | +$430K | 6.1% |
quarter ended March 31, 2022 · filed May 12, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Singular Genomics Systems Inc | Trimmed | −3,000,000 | −$18.9M | 51.2% |
| 2H 23andme Holding Co | Trimmed | −2,000,000 | −$7.66M | 37.4% |
| Somalogic Inc | Exited | −370,839 | −$4.32M | — |
| Neuropace Inc | Trimmed | −285,835 | −$2.35M | 11.4% |
| Natera Inc | Exited | −7,923 | −$739K | — |
| Cvrx Inc | Exited | −38,182 | −$467K | — |
Loading...
